Founded in 2006, the company is located in Taizhou City, Zhejiang Province, the most dynamic chemical API manufacture base in southeastern China.
Engaged in the production and sales of APIs like X-CT non-ionic iodine contrast agents, Hichi has obtained a number of invention patents. We has passed the CFDA’s GMP certification for APIs, as well as certifications such as ISO9001 quality management system, ISO14001 environmental system, and OHSAS18001 Occupational Health and Safety Assessment Series.
ZHEJIANG HICHI PHARMACEUTICAL CORPORATION LIMITED was established
In November, 2006, the pre-evaluation safety report of “GMP technical transformation project of 60 tons/year iodine contrast agent pharmaceutical raw material drug ” passed the review of the expert review team.
In 2009, Obtained the registration certificate of iohexol. In April of the same year, Hichi Pharmaceutical signed an agreement with Xiamen University to carry out technical research and development cooperation on the production technology of iopromide, a contrast-enhancing agent (contrast agent) for medical CT.
In April, 2010 Hichi Pharmaceutical obtained GB/T 19001-2008/ISO 9001: 2008 quality management system certification.
In November, 2015, the company Hichi Pharmaceutical successfully landed on the New Third Board. (Stock code 834402)
In October, 2016, Hichi purchased 75 acres of land and settled in Shamen Bingang Industrial City.
In 2018, Beilu Pharmaceutical takes a stake in Hichi Pharmaceutical
In July, 2020, the company’s annual output of 850 tons of iodine contrast agent production line technical transformation project was put into trial production.
In March, 2021, the company passed the GMP audit, and in July passed the safety and environmental protection completion acceptance and obtained the safety production license.
In 2021, Received capital injection from Beijing Telford Assets in November